Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Breast 2Head & Neck 1Genitourinary 1Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

pembrolizumab 36Capecitabine 28Trastuzumab 23Paclitaxel 22Surveys and Questionnaires 20Cyclophosphamide 20Gemcitabine 18Docetaxel 18Carboplatin 15Nivolumab 14Methods 14Magnetic Resonance Spectroscopy 13Early Intervention, Educational 13Bevacizumab 13Interviews as Topic 12Blood Specimen Collection 12fludarabine 11Standard of Care 11Irinotecan 11olaparib 10durvalumab 10Specimen Handling 10Psychiatric Rehabilitation 10palbociclib 9aldesleukin 9Taxes 9Fulvestrant 9Fluorouracil 9Exercise 9Drug Therapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × enfortumab vedotin × Gastrointestinal × Clear all
NCT04225117 2026-04-13

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Astellas Pharma Inc

Phase 2 Active not recruiting
329 enrolled 23 charts
BreastGastrointestinalHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡